AUG 17, 2021 8:00 AM PDT

Severe daytime sleepiness? A new drug can help: FDA approves Xywav to treat idiopathic hypersomnia.

WRITTEN BY: J. Bryce Ortiz

Being tired throughout the day is a common feeling for most individuals. In fact, 1 out of every 5 Americans see a doctor with complaints of daytime sleepiness. However, for some individuals, daytime sleepiness can be excessive and lead to significant challenges with school, work, and social relationships. This excessive daytime sleep is called hypersomnia. While some forms of hypersomnia have known causes, such as medical conditions, one form of hypersomnia, called idiopathic hypersomnia has no known cause. 

Idiopathic hypersomnia is a rare sleep-related disorder and is characterized by excessive daytime fatigue even after a full, uninterrupted night of sleep. Individuals with this disorder often sleep longer than normal (more than 9-10 hours a night) but never feel rested and have difficulty waking, staying awake, and show reduced focus and concentration throughout the day. 

Recent work by some researchers has tested the effects of a drug for the treatment of idiopathic hypersomnia. Last week, the U.S. Food and Drug Administration (FDA) approved a novel drug called Xywav(calcium, magnesium, potassium, and sodium oxybates) for the treatment of idiopathic insomnia. The pharmaceutical company, Jazz Pharmaceuticals, gained approval to manufacture and market the drug in the United States. 

The approval of the drug is seen as a significant step in the treatment of this rare disorder. However, some are weary of the novel drug due to the fast approval and potential abuse and addictive potential. The key ingredients of the drug resemble the street drug GHB, which is also known as liquid ecstasy. However, one of the lead researchers, Yves Dauvilliers, stated that, “The clinical program for Xywav has demonstrated that [the drug] is an effective therapy for the treatment of idiopathic hypersomnia […] and is a significant step forward for patients.” The drug is a first of its kind treatment for this rare sleep disorder and offers an opportunity for patients to take back their day from the grips of excessive sleepiness. This unique medical condition can have a significant impact on the lives of those diagnosed with the disorder and, as Bruce Cozadd, CEO of Jazz Pharmaceuticals, said, “Xywav is a meaningful treatment for patients […] living with idiopathic hypersomnia who currently have no FDA-approved options available.” 

 

Sources: Sleep FoundationHypersomnia FoundationSleep MedicineNeurologyDrugs.comJazz PharmaceuticalsNew York Times

About the Author
  • Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
AUG 10, 2021
Immunology
A Tapeworm Drug as a COVID Antiviral?
AUG 10, 2021
A Tapeworm Drug as a COVID Antiviral?
A study by researchers at the Scripps Research Institute looking into potential COVID-19 medications has revealed a surp ...
SEP 07, 2021
Neuroscience
Researchers Harness the Power of Machine Learning to Facilitate Drug Repurposing
SEP 07, 2021
Researchers Harness the Power of Machine Learning to Facilitate Drug Repurposing
Using machine learning and massive data sets from patients, researchers identify drug and drug combinations that could b ...
SEP 20, 2021
Genetics & Genomics
Clinical Trial of CRISPR-Based HIV Treatment Set to Begin
SEP 20, 2021
Clinical Trial of CRISPR-Based HIV Treatment Set to Begin
Human immunodeficiency virus (HIV) is a retrovirus, which is a type of virus that can write its genetic material into th ...
OCT 04, 2021
Genetics & Genomics
Zaki syndrome - Pediatric Disorder & Potential Treatment ID'ed
OCT 04, 2021
Zaki syndrome - Pediatric Disorder & Potential Treatment ID'ed
Since it's become quick and relatively inexpensive to sequence a human genome, researchers have gained unprecedented and ...
OCT 12, 2021
Drug Discovery & Development
Preventing future pandemics - Scientists developing broadly protective vaccines against coronaviruses
OCT 12, 2021
Preventing future pandemics - Scientists developing broadly protective vaccines against coronaviruses
Researchers at Japan’s Osaka University recently developed and tested a novel vaccine that may protect a ...
OCT 21, 2021
Coronavirus
FDA approves mixing and matching COVID booster shots
OCT 21, 2021
FDA approves mixing and matching COVID booster shots
On Wednesday, the United States Food and Drug Administration (FDA) approved Americans to be given a different ...
Loading Comments...